A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the long-term safety, tolerability,
immunogenicity, pharmacokinetics and pharmacodynamics of intravenous AEB1102 in patients who
complete Study CAEB1102-101A.